A New Jersey jury awarded 7.76 million dollars for punitive damages and $3.35 million for compensatory damages, to a South Dakota woman injured by a Johnson & Johnson vaginal mesh product. Continue reading ⇒
In the first of 1,800 transvaginal mesh cases to go to trial, the plaintiff opened to the jury stating Johnson & Johnson (JNJ) sold a defective vaginal mesh implant after testing it inadequately and failing to warn of all the risks. Continue reading ⇒
On August 16, 2011 the United States Judicial Panel on Multidistrict Litigation ordered that all pending federal cases involving injuries or deaths alleged to have been caused by the use of Darvocet, Darvon or generic Propoxyphene would be consolidated in MDL 2226. The Court accepted the defendants first choice of the Eastern District of Kentucky as site of the MDL. Read more »
A study published July 5, 2011, in the Archives of General Psychiatry, Antidepressant Use During Pregnancy and Childhood Autism Spectrum Disorders, reports that mothers exposed to SSRI antidepressants during pregnancy, such as Paxil, Zoloft or Prozac, have an increased of having a child born with autism.
Read more »
According to a market research study prepared by GlobalData, in 2009 DePuy held a 21% market share of the global hip and knee replacement market. This leads to the conclusion that as many 1 in 5 hip implant recipients have had DePuy devices installed and are now subject to the recall. Read more »
In an almost unprecedented joint announcement, the FDA and European regulators announced that access to Avandia, a medication to treat diabetes marketed by GlaxoSmithKline, will be severely restricted. Read more »
Today it was reported that GSK has settled more than 700 Avandia cases for a sum reported to be approximately 60 million dollars. These are the first reported settlements involving the drug and represent a small fraction of the total claims believed to be pending. The average settlement would appear to be around 90-95 thousand dollars per case. Read more »
On April 13, 2010 Reuters published a sales forecast predicting the ten top selling drugs for 2014. Contained on that blockbuster list are three drugs, Advair, Remicade and Crestor, which have drawn the scrutiny of consumer safety monitors and attorneys representing injured patients.
Consensus of sales forecasts for world's top 10 drugs in 2014: Read more »